Fundamental Analysis of PRAXIS PRECISION MEDICINES I(NASDAQ:PRAX) stock

Fundamental Rating

PRAX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 586 industry peers in the Biotechnology industry. While PRAX has a great health rating, there are worries on its profitability. While showing a medium growth rate, PRAX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

PRAX had negative earnings in the past year.

PRAX had a negative operating cash flow in the past year.

In the past 5 years PRAX always reported negative net income.

PRAX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -50.07%, PRAX is in line with its industry, outperforming 48.38% of the companies in the same industry.

PRAX has a Return On Equity of -54.58%. This is in the better half of the industry: PRAX outperforms 63.08% of its industry peers.

		Industry Rank	Sector Rank
ROA	-50.07%
ROE	-54.58%
ROIC	N/A

ROA(3y)-127.73%

ROA(5y)-98.33%

ROE(3y)-174.93%

ROE(5y)-130.14%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRAX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.

PRAX has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, PRAX has less shares outstanding

PRAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 17.82 indicates that PRAX is not in any danger for bankruptcy at the moment.

PRAX's Altman-Z score of 17.82 is amongst the best of the industry. PRAX outperforms 91.11% of its industry peers.

PRAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	17.82

ROIC/WACCN/A

WACC9.02%

2.3 Liquidity

A Current Ratio of 11.27 indicates that PRAX has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 11.27, PRAX belongs to the top of the industry, outperforming 80.68% of the companies in the same industry.

PRAX has a Quick Ratio of 11.27. This indicates that PRAX is financially healthy and has no problem in meeting its short term obligations.

PRAX has a better Quick ratio (11.27) than 80.85% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	11.27
Quick Ratio	11.27

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PRAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.95%, which is quite impressive.

Looking at the last year, PRAX shows a very strong growth in Revenue. The Revenue has grown by 222.94%.

EPS 1Y (TTM)38.95%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q73.33%

Revenue 1Y (TTM)222.94%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q-37.04%

3.2 Future

The Earnings Per Share is expected to grow by 20.38% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 188.41% on average over the next years. This is a very strong growth

EPS Next Y61.3%

EPS Next 2Y25.85%

EPS Next 3Y20.51%

EPS Next 5Y20.38%

Revenue Next Year16.66%

Revenue Next 2Y-13.58%

Revenue Next 3Y245.45%

Revenue Next 5Y188.41%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRAX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRAX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PRAX's earnings are expected to grow with 20.51% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y25.85%

EPS Next 3Y20.51%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PRAX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PRAXIS PRECISION MEDICINES I

NASDAQ:PRAX (5/17/2024, 7:20:57 PM)

After market: 45.39 0 (0%)

45.39

+0.18 (+0.4%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap776.62M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-50.07%
ROE	-54.58%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	11.27
Quick Ratio	11.27
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)38.95%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y61.3%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)222.94%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PRAXIS PRECISION MEDICINES I (PRAX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens